1784

BIONETTPEX:1784 Stock Report

Market Cap

NT$2.1b

7D

-5.5%

1Y

5.7%

Updated

18 Sep, 2021

Data

Company Financials +
1784 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

1784 Overview

BIONET Corp. provides cord blood banking services in Taiwan and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for BIONET
Historical stock prices
Current Share PriceNT$43.25
52 Week HighNT$35.15
52 Week LowNT$51.90
Beta0.83
1 Month Change-3.03%
3 Month Change0.23%
1 Year Change5.75%
3 Year Change33.08%
5 Year Change35.16%
Change since IPO204.61%

Recent News & Updates

Apr 10
Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

BIONET Corp. ( GTSM:1784 ), is not the largest company out there, but it saw a significant share price rise of over 20...

Feb 10
If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

Investors can buy low cost index fund if they want to receive the average market return. But across the board there are...

Shareholder Returns

1784TW HealthcareTW Market
7D-5.5%-0.6%-1.1%
1Y5.7%-5.5%33.6%

Return vs Industry: 1784 exceeded the TW Healthcare industry which returned -5.5% over the past year.

Return vs Market: 1784 underperformed the TW Market which returned 33.6% over the past year.

Price Volatility

Is 1784's price volatile compared to industry and market?
1784 volatility
1784 Beta0.83
Industry Beta0.61
Market Beta1

Stable Share Price: 1784 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 1784's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/aTian Liuhttps://www.bionetcorp.com

BIONET Corp. provides cord blood banking services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC + immune cells; and genetic testing services. It also provides stem anti-aging, rose stem rejuvenation, ultimate protection and repair, and ANIKINE series products.

BIONET Fundamentals Summary

How do BIONET's earnings and revenue compare to its market cap?
1784 fundamental statistics
Market CapNT$2.05b
Earnings (TTM)NT$31.33m
Revenue (TTM)NT$904.11m

65.5x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1784 income statement (TTM)
RevenueNT$904.11m
Cost of RevenueNT$428.21m
Gross ProfitNT$475.90m
ExpensesNT$444.57m
EarningsNT$31.33m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.66
Gross Margin52.64%
Net Profit Margin3.47%
Debt/Equity Ratio0%

How did 1784 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

27%

Payout Ratio

Valuation

Is BIONET undervalued compared to its fair value and its price relative to the market?

65.53x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1784 (NT$43.25) is trading above our estimate of fair value (NT$24.46)

Significantly Below Fair Value: 1784 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1784 is poor value based on its PE Ratio (65.5x) compared to the TW Healthcare industry average (18.2x).

PE vs Market: 1784 is poor value based on its PE Ratio (65.5x) compared to the TW market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1784's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1784's PB Ratio (1.9x) is in line with the TW Healthcare industry average.


Future Growth

How is BIONET forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

20.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIONET has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has BIONET performed over the past 5 years?

43.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1784 has high quality earnings.

Growing Profit Margin: 1784's current net profit margins (3.5%) are higher than last year (0.6%).


Past Earnings Growth Analysis

Earnings Trend: 1784's earnings have grown significantly by 43.6% per year over the past 5 years.

Accelerating Growth: 1784's earnings growth over the past year (629%) exceeds its 5-year average (43.6% per year).

Earnings vs Industry: 1784 earnings growth over the past year (629%) exceeded the Healthcare industry -2.8%.


Return on Equity

High ROE: 1784's Return on Equity (2%) is considered low.


Financial Health

How is BIONET's financial position?


Financial Position Analysis

Short Term Liabilities: 1784's short term assets (NT$822.4M) exceed its short term liabilities (NT$237.4M).

Long Term Liabilities: 1784's short term assets (NT$822.4M) exceed its long term liabilities (NT$215.2M).


Debt to Equity History and Analysis

Debt Level: 1784 is debt free.

Reducing Debt: 1784 has not had any debt for past 5 years.

Debt Coverage: 1784 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1784 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is BIONET current dividend yield, its reliability and sustainability?

0.42%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1784's dividend (0.42%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).

High Dividend: 1784's dividend (0.42%) is low compared to the top 25% of dividend payers in the TW market (5.25%).


Stability and Growth of Payments

Stable Dividend: 1784 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.

Growing Dividend: 1784 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 1784 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1784's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.3yrs

Average board tenure


CEO

Tian Liu

15yrs

Tenure

Tian Lai Liu has been President of BIONET Corp. since September 1, 2006. Tian Lai Liu serves as General Manager at Bionet Corp. Tian Lai Liu served as Franchise Manager at J&J Medical Taiwan and Supervisor...


Board Members

Experienced Board: 1784's board of directors are seasoned and experienced ( 15.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BIONET Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: BIONET Corp.
  • Ticker: 1784
  • Exchange: TPEX
  • Founded: 1999
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: NT$2.053b
  • Shares outstanding: 47.48m
  • Website: https://www.bionetcorp.com

Location

  • BIONET Corp.
  • No.28, Xinhu 1st Road
  • Lane 36
  • Taipei City
  • 11494
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 08:32
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.